- $83.81bn
- $101.99bn
- £31.38bn
- 70
- 69
- 83
- 88
REG - GlaxoSmithKline PLC - positive results in Phase 3 PRIMA study of ZEJULA
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - ViiV switch study shows 2DR as effective as 3DR
AnnouncementREG - GlaxoSmithKline PLC - ViiV receives Dovato EU Marketing Authorisation
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - FDA approval for Nucala self-administration
AnnouncementREG - GlaxoSmithKline PLC - CHMP positive on GSK's Nucala self-administration
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Block listing Interim Review
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Result of AGM & GM
AnnouncementREG - GlaxoSmithKline PLC - Trelegy Ellipta asthma study met primary endpoint
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
Announcement